Live News REGULATION L impact Jul 15, 2026, 11:15 AM UTC

RHHBY FDA grants Priority Review to Roche's Gazyva/Gazyvaro for adults with primary membranous nephropathy

RHHBY FDA grants Priority Review to Roche's Gazyva/Gazyvaro for adults with primary membranous nephropathy

SquawkNews Newsroom

RHHBY FDA grants Priority Review to Roche's Gazyva/Gazyvaro for adults with primary membranous nephropathy